NEW YORK CITY, NY / ACCESS Newswire / August 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ:SLNO). Investors who purchased Soleno securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SLNO.
Investigation Details
On August 15, 2025, Investing.com published a report entitled "Soleno Therapeutics stock falls after Scorpion Capital short report." The report stated that Soleno stock had dropped "following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi syndrome treatment, VYKAT XR." The report continued to state that the Scorpion Capital report "highlighted personal safety issues," and that it "suggested the drug may be at risk of being withdrawn from the market or facing a significant decline in new prescriptions." Following this news, Soleno stock dropped 7.4% on August 15, 2025, and dropped another 4.9% on the next trading day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Soleno securities, you can assist this investigation by visiting the firm’s site: bgandg.com/SLNO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_468342902/2457/2025-08-27T11:01:45